<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684109</url>
  </required_header>
  <id_info>
    <org_study_id>20180606</org_study_id>
    <nct_id>NCT03684109</nct_id>
  </id_info>
  <brief_title>Non-invasive Glioma Characterization Through Molecular Imaging</brief_title>
  <official_title>Pilot Study for Non-invasive Glioma Characterization Through Molecular Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI-based sequences can provide non-invasive quantification of intratumoral&#xD;
      2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide&#xD;
      the development of novel glioma therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study aiming at developing and optimizing MRI-based sequences to provide&#xD;
      non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor&#xD;
      cellularity in human gliomas and help guide the development of novel glioma therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily closed to accrual due to COVID-19 pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2HG Concentration via 3T MRI Scanner</measure>
    <time_frame>Day 1</time_frame>
    <description>2HG concentrations as measured via 3T MRI Scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2HG Concentration from tissue samples</measure>
    <time_frame>Day 1</time_frame>
    <description>2HG concentrations as measured via patient's surgically excised tissue sample ex vivo by tissue based liquid chromatography-mass spectrometry (LC-MS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioma</condition>
  <condition>Brain Tumor</condition>
  <condition>Primary Brain Tumor</condition>
  <condition>Malignant Glioma</condition>
  <condition>Malignant Primary Brain Tumor</condition>
  <arm_group>
    <arm_group_label>IDH-Mutant Glioma Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have suspected or confirmed gliomas and are scheduled to undergo biopsy or resection of their brain tumors will receive a 3 Tesla (3T) Magnetic Resonance Imaging (MRI) scan of their brain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3T MRI Scanner</intervention_name>
    <description>3T MRI Scanner providing Mega-laser sequence for single-voxel Magnetic Resonance Spectroscopy (MRS) data for 2 hydroxyglutarate (2HG) quantitation.</description>
    <arm_group_label>IDH-Mutant Glioma Patients</arm_group_label>
    <other_name>3 Tesla (3T) Magnetic Resonance Imaging Scanner</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (â‰¥18 year old)&#xD;
&#xD;
          -  Subjects with suspected or confirmed gliomas and who will have a medically indicated&#xD;
             biopsy or resection of his/her brain lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients unable to have MRI done&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Macarena De La Fuente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Macarena De La Fuente, MD</investigator_full_name>
    <investigator_title>Assistance Professor</investigator_title>
  </responsible_party>
  <keyword>Non-invasive glioma characterization</keyword>
  <keyword>Molecular Imaging</keyword>
  <keyword>Isocitrate Dehydrogenase (IDH) Mutations</keyword>
  <keyword>MRI-Based Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

